Targeting angiogenesis for radioimmunotherapy with a ¹⁷⁷Lu-labeled antibody.

ABSTRACT:

Purpose

Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy.

Methods

The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with ¹⁷⁷Lu (t _1/2 6.65 days). Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: ¹⁷⁷Lu only, TRC105 only, ¹⁷⁷Lu-DTPA-IgG (a nonspecific antibody), ¹⁷⁷Lu-DTPA

SUBMITTER: Ehlerding EB 

PROVIDER: S-EPMC5700843 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature